Saxenda Dosage in 2026: What Clinicians Actually Prescribe

Saxenda at a glance:

• Drug class: GLP-1 receptor agonist
• Manufacturer: Novo Nordisk
• FDA approved: 2014
• Route: subcutaneous injection (multi-dose pen)
• Typical frequency: once daily
• Half-life: approximately 13 hours
• Cash price (US): $1,200-$1,400/month without insurance
• Receptor target: GLP-1 receptor

The wrong Saxenda dose — too high, too low, or escalated too quickly — is the most common reason people stop the drug. Saxenda titrates weekly: 0.

Standard Dosing Schedule for Saxenda

Saxenda titrates weekly: 0.6 → 1.2 → 1.8 → 2.4 → 3.0 mg/day. The full 3.0 mg dose drives the weight-loss benefit.

The typical schedule for Saxenda is once daily via subcutaneous injection (multi-dose pen). Half-life of approximately 13 hours explains why this schedule works — the drug stays active long enough to support that interval.

Titration: Why Starting Low Matters

For incretin therapies, gradual titration is the standard approach. The starting doses listed above are not therapeutic — they exist to let the body adapt and to reduce gastrointestinal symptoms (nausea, vomiting, diarrhea).

A typical titration plan for Saxenda holds each dose step for at least four weeks before moving up. Faster titration is associated with more dropouts due to side effects.

Missed Doses

If a dose of Saxenda is missed: for daily schedules, the rule of thumb is to take it as soon as remembered if within a defined window, otherwise skip it and resume the regular schedule. The exact window depends on the half-life (approximately 13 hours) and the specific product label. Never double up to make up for a missed dose.

Dose Adjustments

Dose adjustments may be needed for the following:

• Significant weight loss or weight gain
• Side-effect intolerance at the current step
• Changes in renal or hepatic function
• Drug interactions (particularly relevant for any concurrent medications)

We cover the side-effect side of dose decisions in Saxenda side effects and the cost angle of dose escalation in Saxenda cost.

What the Trials Used

Published trial data for Saxenda comes primarily from: SCALE Obesity (Pi-Sunyer 2015, NEJM) — 9.2% mean weight loss vs 3.5% placebo at 56 weeks.

That data drives the labeled dosing range, which is what physicians prescribe by.

Special Populations

The dosing guidance above applies to general adult use. Special populations — pregnancy, pediatric, severe renal impairment, hepatic dysfunction, elderly with frailty — require individualized assessment that this page can't substitute for.

For Saxenda: the personal or family history of medullary thyroid carcinoma, MEN 2 syndrome, pregnancy apply.

Bottom Line

Most Saxenda dose questions resolve in a 5-minute conversation with a clinician. Don't carry them around — get them answered.

Frequently Asked Questions

Related Reading

• Saxenda Explained: How It Works and Who It's For
• Saxenda Side Effects Decoded: What's Normal vs. What Isn't
• Does Saxenda Really Work? An Evidence-Based Results Review
• Saxenda Price Decoded: Insurance, Coupons, and Cash-Pay Options
• What Is Ozempic? Everything You Should Know Before Starting
• Is Ozempic Safe? An Honest Look at the Side-Effect Profile

Sources

• Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. NEJM 2021;384:989.
• Marso SP et al. Semaglutide and Cardiovascular Outcomes in Type 2 Diabetes (SUSTAIN-6). NEJM 2016;375:1834.
• Pi-Sunyer X et al. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management (SCALE). NEJM 2015;373:11.

This page is informational only and is not medical advice. Always follow your prescribing clinician's dosing instructions.